literature

HIV mutation literature information.

Dimerization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir.

PMID: 25092296 2014 Proc Natl Acad Sci U S A

Abstract: Notably, DRV failed to bind to mutant PR containing four amino acid substitutions (V32I, L33F, I54M, and I84V) that confer resistance to DRV on HIV-1.

Transmitted antiretroviral drug resistance mutations in newly diagnosed HIV-1 positive patients in Turkey.

PMID: 25397495 2014 Journal of the International AIDS Society

Abstract: RESULTS: The patients had TDRMs to NRTIs (K65R, M184V), NNRTIs (K101E, K103N/S, G190A/E/S, Y181I/C, Y188H/L) and PIs (M46L, I54V, L76V, V82L/T, N83D, I84V, L90M).

The role of mutations at codons 32, 47, 54, and 90 in HIV-1 protease flap dynamics.

PMID: 32309558 2014 Discoveries (Craiova, Romania)

Method: All three isolates contain the L33F, M46I, and I84V major drug resistance mutations and the I13V accessory mutation.

Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial.

PMID: 25926858 2014 AIDS research and therapy

Abstract: Of 15/313 patients who met the criteria for resistance analysis, one developed a darunavir RAM as

Method: Patients were required to have plasma VL >=1000 HIV-1 RNA copies/ml (Amplicor HIV-1 Monitor Test, version 1.5, Roche Diagnostics, Basel, Switzerland) at screening, eGFRCG >=80 ml/min, genotypic sensitivity to the two investigator-selected N[t]RTIs (GenoSure MG assay, Monogram Biosciences, South San Francisco, CA, USA), and none of the following darunavir RAMs: V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V or L89V.

Lamivudine plus darunavir boosted with ritonavir as simplification dual regimen in HIV-infected patients.

PMID: 25397545 2014 Journal of the International AIDS Society

Abstract: In eight cases, a previous resistance test showed two to seven secondary mutations in the protease gene, without resistance to DRV/r (one patient with the I84V mutation).

Use of dolutegravir in two INI-experienced patients with multiclass resistance resulted in excellent virological and immunological responses.

PMID: 25397500 2014 Journal of the International AIDS Society

Table: I84V

A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses.

PMID: 25259833 2014 AIDS (London, England)

Result: Of the 243 patients who received one or more protease inhibitors, 32 (13%) had a study-defined protease inhibitor-resistance mutation most commonly L10F, K20T, V32I, L33F, M46I/L, I47V/A, I50L, F53L, I54V/L, Q58E, L76V, V82A/C, I84V, L89V, and L90M.

A multi-drug resistant HIV-1 protease is resistant to the dimerization inhibitory activity of TLF-PafF.

PMID: 25108107 2014 Journal of molecular graphics & modelling

Introduction: The multidrug-resistant (MDR)-769 HIV-1 protease consists of amino acid substitutions: L10I, M36V, M46L, I54V, I62V, L63P, A71V, V82A, I84V and L90M.

2014 Update of the drug resistance mutations in HIV-1.

PMID: 25101529 2014 Topics in antiviral medicine

Discussion: The negative impact of the protease mutations I47V, I54M, T74P, and I84V and the positive impact of the protease mutation V82A on virologic response to darunavir/ritonavir were shown in 2 data sets independently.

Discussion: Their impacts differ, with I50L, I84V, and N88S having the greatest effect.

Revealing origin of decrease in potency of darunavir and amprenavir against HIV-2 relative to HIV-1 protease by molecular dynamics simulations.

PMID: 25362963 2014 Scientific reports

Result: Mutations that confer major resistance in PR1, such as G48V, L63P and I84V weaken or do not present these interactions, which basically agrees with our studies here.

Browser Board

Co-occurred Entities

Filtrator